Market Overview

Gene Therapy for Ovarian Cancer - A Pipeline Analysis | Technavio


market research company announces their latest report on gene
therapy for ovarian cancer
2018-2022. The market research report
provides a detailed study for ovarian cancer along with the pipeline
landscape. It consists of a comparative analysis and indication
analysis. The report also lists out the major regulatory authorities in
different geographies.

This press release features multimedia. View the full release here:

Technavio has published a new market research report on gene therapy for ovarian cancer from 2018-20 ...

Technavio has published a new market research report on gene therapy for ovarian cancer from 2018-2022. (Graphic: Business Wire)

Gene therapy for ovarian cancer - market

Several types of cells within the ovary leads to ovarian
and has the lowest survival rate of all gynecological
cancers. Epithelial ovarian cancer (EOC) is the most common type of
ovarian cancer whereas ovarian low malignant potential tumor (OLMPT),
germ cell tumor, and stromal ovarian tumor are some of the less common

The immunotherapy market for ovarian cancer has some commercially
successful chemotherapy products. Chemotherapy is a combination of two
or more drugs that is given after every 3-4 weeks and has a long-lasting
aide/adverse effects. Studies have shown that chemotherapy can damage
the blood-producing cells of bone marrow that results in blood related

This report is available at a USD 1,000 discount for a limited time
market snapshot before purchasing

Save more with Technavio. Buy 2 reports and get the
third for FREE:
all Technavio's current offers

Gene therapy is expected to be one of the next big paradigm shift in
pharmacology due to the extensive on-going research studies, both at
academic and industry level.

According to a senior analyst at Technavio for oncology,
"Gene therapy is one of the most exciting approaches for the treatment
of ovarian cancer. Replacement gene therapy is gaining attention as it
has the potential to cure ovarian cancer and can be used as a promising
option for long-lasting treatment."

Looking for more information on this market? Request
a free sample report

Technavio's sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.

Gene therapy for ovarian cancer - segmentation

The gene
therapy for ovarian cancer
is segmented on the basis of the type
of ovarian cancer (ovarian cancer (unspecified), recurrent ovarian
epithelial cancer, and platinum-resistant ovarian cancer) and RoA
(intraperitoneal, intravenous, intratumoral, and unspecified).

The report also consists of companies that are actively involved in the
development of gene therapy for ovarian cancer. Based on their financial
status, the companies are segmented into Tier-1, Tier-2, and Tier-3.


Technavio's best deals of the month!


Celebrate Earth Day and clean energy with Technavio. Get 30% discount
on all Energy
. Offer valid from 12th March - 18th




Get 20% off on all Media
and Entertainment Services reports
. Offer valid only till
the 31st of March.


About Technavio

is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio's comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team

View Comments and Join the Discussion!